IS7148A - Aðferðir til að framleiða kalsíumsaltform statína - Google Patents
Aðferðir til að framleiða kalsíumsaltform statínaInfo
- Publication number
- IS7148A IS7148A IS7148A IS7148A IS7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A
- Authority
- IS
- Iceland
- Prior art keywords
- statins
- methods
- salt form
- calcium salt
- producing calcium
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 159000000007 calcium salts Chemical group 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31281201P | 2001-08-16 | 2001-08-16 | |
| US10/037,412 US6528661B2 (en) | 2000-11-16 | 2001-10-24 | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| PCT/US2002/026012 WO2003016317A1 (en) | 2001-08-16 | 2002-08-16 | Processes for preparing calcium salt forms of statins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7148A true IS7148A (is) | 2004-02-11 |
Family
ID=26714105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7148A IS7148A (is) | 2001-08-16 | 2004-02-11 | Aðferðir til að framleiða kalsíumsaltform statína |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1425287A4 (is) |
| JP (2) | JP4188826B2 (is) |
| CN (1) | CN100430405C (is) |
| AU (1) | AU2002324715B2 (is) |
| CA (1) | CA2450820C (is) |
| CZ (1) | CZ2004337A3 (is) |
| HR (1) | HRPK20040255B3 (is) |
| HU (1) | HUP0500616A3 (is) |
| IL (2) | IL160077A0 (is) |
| IS (1) | IS7148A (is) |
| MX (1) | MXPA04001451A (is) |
| NO (1) | NO20041082L (is) |
| NZ (1) | NZ529913A (is) |
| PL (1) | PL370407A1 (is) |
| SK (1) | SK1402004A3 (is) |
| TR (1) | TR200302281T2 (is) |
| WO (1) | WO2003016317A1 (is) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| HRP20030454A2 (en) * | 2000-11-16 | 2005-10-31 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| EP1485343B1 (en) | 2002-03-18 | 2009-12-23 | Biocon Limited | Amorphous hmg-coa reductase inhibitors of desired particle size |
| EA200401533A1 (ru) * | 2002-05-21 | 2005-06-30 | Ранбакси Лабораторис Лимитед | Способ получения росувастатина |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| WO2004072040A1 (en) * | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
| ES2323366T3 (es) | 2003-04-22 | 2009-07-14 | Biocon Limited | Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres. |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| US7414141B2 (en) | 2003-07-25 | 2008-08-19 | Avecia Pharmaceuticals, Ltd. | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin |
| WO2005019170A1 (en) * | 2003-08-26 | 2005-03-03 | Biocon Limited | Novel process for preparation of 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3, 5-dihydroxy-6-heptenoic acid sodium salt |
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| EP1816126A1 (en) * | 2003-08-28 | 2007-08-08 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| WO2005026107A1 (en) | 2003-09-18 | 2005-03-24 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| EP1678148A1 (en) * | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
| GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| CN1894221B (zh) * | 2003-12-02 | 2012-08-08 | 特瓦制药工业有限公司 | 用于表征罗苏伐他汀的参照标准品 |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| CA2551549A1 (en) * | 2003-12-29 | 2005-07-14 | Lek Pharmaceuticals D.D. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
| CZ200486A3 (cs) * | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
| EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
| US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
| SI21745A (sl) * | 2004-04-09 | 2005-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
| WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| KR20070038553A (ko) * | 2004-08-06 | 2007-04-10 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 스타틴 약제학적 조성물 및 관련된 치료방법 |
| TWI345562B (en) | 2005-02-22 | 2011-07-21 | Teva Pharma | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
| JP2009515816A (ja) * | 2005-08-04 | 2009-04-16 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 |
| KR20070062996A (ko) | 2005-08-16 | 2007-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 로수바스타틴 중간체 |
| CN100371709C (zh) * | 2005-12-12 | 2008-02-27 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法 |
| SI2024341T1 (sl) * | 2006-05-03 | 2016-04-29 | Msn Laboratories Private Limited | Novi postopek za statine in njihove farmacevtsko sprejemljive soli |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| EP2022784A1 (en) | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Process for the preparation of methyl ester of rosuvastatin |
| US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| EP2526099B1 (en) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| WO2012063254A1 (en) * | 2010-11-12 | 2012-05-18 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| HU229260B1 (en) * | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
| CN102875504A (zh) * | 2011-07-13 | 2013-01-16 | 华南理工大学 | 4,5,6,7-四氢普伐他汀及其盐在心血管上的用途 |
| CN102302452B (zh) * | 2011-09-14 | 2012-11-21 | 海南美大制药有限公司 | 匹伐他汀钙脂质体固体制剂 |
| CN102796036B (zh) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | 一种阿托伐他汀钙的制备方法 |
| CN103724278B (zh) * | 2013-12-12 | 2019-03-29 | 江苏阿尔法药业有限公司 | 他汀类中间体及其衍生物的制备方法 |
| CN106029895B (zh) | 2014-02-06 | 2021-07-16 | 株式会社Api | 瑞舒伐他汀钙及其中间体的生产方法 |
| KR20160126700A (ko) | 2015-04-24 | 2016-11-02 | 미래파인켐 주식회사 | 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법 |
| CN105111173B (zh) * | 2015-06-26 | 2017-06-23 | 上海应用技术学院 | 他汀含氟衍生物及其用途 |
| CN105017231B (zh) * | 2015-06-26 | 2018-01-26 | 上海应用技术学院 | 多取代吲哚类他汀含氟修饰物及其用途 |
| EP3333155B1 (en) | 2015-08-05 | 2023-05-24 | API Corporation | Method for producing pitavastatin calcium |
| CN111362856B (zh) * | 2020-04-29 | 2023-08-18 | 福建海西新药创制股份有限公司 | 一种利用微反应装置生产阿托伐他汀钙的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4137322A (en) * | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
| JPS5817443B2 (ja) * | 1976-11-02 | 1983-04-07 | 三共株式会社 | Ｍｌ−２３６ｂ金属塩を主成分とする高脂血症治療剤 |
| US4857547A (en) * | 1988-01-07 | 1989-08-15 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| US5669156A (en) * | 1996-08-28 | 1997-09-23 | Fleetwood Systems, Inc. | Can end curing system with magnetic fanning and belt conveying |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| JP2002538202A (ja) * | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩 |
| HRP20030454A2 (en) * | 2000-11-16 | 2005-10-31 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2007205725A1 (en) * | 2000-11-30 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2431068C (en) * | 2000-12-27 | 2008-06-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
| US7563911B2 (en) * | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
-
2002
- 2002-08-16 CA CA2450820A patent/CA2450820C/en not_active Expired - Fee Related
- 2002-08-16 IL IL16007702A patent/IL160077A0/xx active IP Right Grant
- 2002-08-16 EP EP02759374A patent/EP1425287A4/en not_active Withdrawn
- 2002-08-16 JP JP2003521239A patent/JP4188826B2/ja not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026012 patent/WO2003016317A1/en not_active Ceased
- 2002-08-16 HR HR20040255A patent/HRPK20040255B3/xx not_active IP Right Cessation
- 2002-08-16 HU HU0500616A patent/HUP0500616A3/hu unknown
- 2002-08-16 PL PL02370407A patent/PL370407A1/xx unknown
- 2002-08-16 SK SK140-2004A patent/SK1402004A3/sk not_active Application Discontinuation
- 2002-08-16 CN CNB028159993A patent/CN100430405C/zh not_active Expired - Fee Related
- 2002-08-16 MX MXPA04001451A patent/MXPA04001451A/es not_active Application Discontinuation
- 2002-08-16 AU AU2002324715A patent/AU2002324715B2/en not_active Expired - Fee Related
- 2002-08-16 TR TR2003/02281T patent/TR200302281T2/xx unknown
- 2002-08-16 CZ CZ2004337A patent/CZ2004337A3/cs unknown
- 2002-08-16 NZ NZ529913A patent/NZ529913A/en unknown
-
2004
- 2004-01-27 IL IL160077A patent/IL160077A/en not_active IP Right Cessation
- 2004-02-11 IS IS7148A patent/IS7148A/is unknown
- 2004-03-15 NO NO20041082A patent/NO20041082L/no not_active Application Discontinuation
-
2008
- 2008-07-15 JP JP2008184147A patent/JP2009024008A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRPK20040255B3 (en) | 2006-02-28 |
| WO2003016317A1 (en) | 2003-02-27 |
| JP4188826B2 (ja) | 2008-12-03 |
| JP2005500382A (ja) | 2005-01-06 |
| JP2009024008A (ja) | 2009-02-05 |
| EP1425287A1 (en) | 2004-06-09 |
| IL160077A (en) | 2007-10-31 |
| CZ2004337A3 (cs) | 2005-01-12 |
| HUP0500616A2 (hu) | 2005-11-28 |
| CA2450820C (en) | 2011-03-15 |
| HRP20040255A2 (en) | 2004-08-31 |
| NZ529913A (en) | 2005-03-24 |
| CA2450820A1 (en) | 2003-02-27 |
| CN100430405C (zh) | 2008-11-05 |
| PL370407A1 (en) | 2005-05-30 |
| SK1402004A3 (sk) | 2005-01-03 |
| HUP0500616A3 (en) | 2011-07-28 |
| EP1425287A4 (en) | 2005-09-07 |
| CN1543468A (zh) | 2004-11-03 |
| NO20041082L (no) | 2004-03-15 |
| AU2002324715B2 (en) | 2009-03-12 |
| IL160077A0 (en) | 2004-06-20 |
| TR200302281T2 (tr) | 2004-09-21 |
| MXPA04001451A (es) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20041082L (no) | Fremgangsmater for fremstilling av kalsiumsaltformer av statiner | |
| IS7728A (is) | Aðferð til að framleiða kalsíumsalt rósuvastatíns | |
| ATE507201T1 (de) | Energiegünstiges carbonylierungsverfahren | |
| DE60205413D1 (de) | Herstellungsverfahren | |
| EP1456132A4 (en) | METHOD OF FRACTIONATED DEHTIONIZATION | |
| FR2821838B1 (fr) | Procede d'allegement de plaques de platre | |
| BR0214746B1 (pt) | mÉtodo de produzir embreagem unidirecional | |
| DK1392609T3 (da) | Fremgangsmåde til inhibering af dannelse af kalciumsaltafsætninger | |
| PL367278A1 (en) | Method for inhibiting calcium salt scale | |
| IS7312A (is) | Aðferð til að ákvarða lífvirkni defíbrótíðs | |
| DE60233109D1 (de) | Radidentifikator- ortungsverfahren | |
| IS6716A (is) | Aðferðir við að framleiða sílostasól | |
| ITMI20021031A0 (it) | Procedimento per preparare policarbonato-polioli | |
| DE60233230D1 (de) | Höhenbildsyntheseverfahren | |
| EP1405844A4 (en) | CYCLOALKENONDERIVAT | |
| FI20010892L (fi) | Menetelmä ksylitolin valmistamiseksi | |
| FI20011252A0 (fi) | Rakennusmenetelmä | |
| EP1384958A4 (en) | PRODUCTION SYSTEM | |
| FI20012552L (fi) | Metallikarbonaatin valmistusmenetelmä | |
| ITMO20010199A0 (it) | Apparato per formare piastrelle | |
| ITMO20010063A0 (it) | Apparato per formare piastrelle | |
| NO20012603L (no) | Undervanns produksjonssystem | |
| IS6928A (is) | Aðferðir til að framleiða mirtasapínmilliefni | |
| ITMI20021432A0 (it) | Metodo per produrre cefalosporine | |
| FR2832600B1 (fr) | Hamac horizontal |